title: [Comparative analysis of three treatment regimens for treating gonarthritis with calcitonin, naproxen and flavonoids based on EULAR criteria and visual analogue scale (VAS)].
abstract: The newest laboratory and clinical elaborations have described a stimulatory effect of salmon calcitonin (sCT) on cultivated chondrocytes and cartilage explants in regard to their secretory function of glycosaminoglycans, collagen t. II and hyaluonic acid as well as have shown anticatabolic effect of sCT on numerous animal models of osteoarthropathy. Moreover, very few clinical indicated profitable effect of CT on degenerative joint diseases and on rheumatoid arthritis. The aim of the present study is to compare the curative effect of sCT (Miacalcic, Sandoz, nasal spray, 2 x 100 IU/day ) vs flavonoides (VR, Venoruton, Zyma, 2 x 0.6 + Vit. C. 0.2/day) with or without naproxen sodium (AP, Apranax, 2 x 0.550/day) in 30 patients suffering from gonarthritis, treated in 10 months in one of the three regimes: I--(n = 10, BMI-33.3, aged 59.5 y., Larsen gr. -2.5): 1st month-VR, 2 and 3-sCT, 4 and 5-VR, 6 and 7-AP, 8.9 and 10-VR; II--(n = 10, BMI-28.8, aged 56 y., Larsen gr. 2.95): 1st m.-VR, 2 and 3-Ap, 4 and 5-VR, 6 and 7-sCT, 9.9 and 10-VR; III--(n = 10, BMI-31.4, aged 58 y., Larsen gr.-2.8): 1st m.-VR, 2 and 3-sCT, 4 and 5-VR, 6 and 7-sCT, 8.9 and 10-VR. Clinical effects of treatment were evaluated by EULAR criteria, VAS, and the paracetamol consumption.
  
  
  RESULTS
  The best results according to all three criteria of improvement have been observed in group III treated only with sCT and VR followed by group I in which sCT was given as the first active drug. This effect lasted until three months after the withdrawal of sCT and/or naproxen. This results supported our opinion on antiosteoarthritic ability of salmon calcitonin and marked curative effect of flavonoides in the treatment of osteoarthritis.
authors.affiliation: Oddziału Chorób Wewnetrznych i Reumatologii Szpitala Wojewódzkiego im. J. Sniadeckiego w Białymstoku.
authors.forename: J
authors.initials: J
authors.lastname: Badurski
authors.forename: E
authors.initials: E
authors.lastname: Jeziernicka
authors.forename: K
authors.initials: K
authors.lastname: Naruszewicz
authors.forename: A
authors.initials: A
authors.lastname: Racewicz
mesh_terms: D002116:Calcitonin / Q000008:administration & dosage*; D002392:Catechin; D002478:Cells, Cultured / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage*; D006801:Humans; D007719:Knee Joint; D008297:Male; D009288:Naproxen / Q000008:administration & dosage*; D010003:Osteoarthritis / Q000188:drug therapy*; D010147:Pain Measurement
chemical_list: D005419:Flavonoids; D009288:Naproxen; D002392:Catechin; D002116:Calcitonin
vernacular_title: Porównawcza analiza trzech schematów leczenia gonarthritis kalcytonina, naprowenem i flaksonoidami w oparciu o kryteria EULAR i wizualna skale analogowa bólu (VAS).